bcbs fep glp-1 coverage 2025 How Employers Can Manage Costs in Their Health Plans What FEHB changes mean for

Following the positive REDEFINE 1 Phase 3 data (published June 2025, PMID: 40544433), Novo Nordisk announced plans to file regulatory applications for CagriSema for obesity in the United States (FDA), European Union (EMA), and other major markets in 20252026

However, some patients may stop because of side effects, cost, and accessibility

Remote, un-monitored pipelines fail to check blood pressure or audit dangerous, standing-induced lightheadedness, exposing patients to severe head trauma or car crashes

Interestingly, this effect was mediated by the release of CCK and GLP-1 and subsequent activation of their receptors, possibly on VANs (see Hormonal gut-brain signaling section)

"Every week, my lawyers and I are playing whack-a-mole with fake AI videos of me selling everything from gummies to pink salt," she wrote